JPMorgan initiates Hemab Therapeutics stock with overweight rating

JPMorgan initiated coverage on Hemab Therapeutics (COAG) with an overweight rating and $70 price target, citing its pipeline for bleeding disorders. The stock is currently at $29.94, 46% below its 52-week high. Analysts project significant revenue potential for its lead assets, sutacimig and HMB-002, with combined revenue estimates of $4.6 billion by 2044. Other analysts have also raised price targets, reflecting positive sentiment.

Original reporting
Published Oct 15, 2026, 7:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 8:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$COAG
Bullish
high confidence
Mentioned
$COAG
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$COAGBullishMed
01

Why it matters

Analyst initiation with a strong price target could drive short-term buying pressure.

02

Market read

New coverage may attract institutional interest and lift the stock.

03

What to watch

Potential regulatory delays or trial setbacks could temper upside.

Relevance 6/10Novelty 6/10Timing: intraday today

Background

Hemab Therapeutics is a biotech developing subcutaneous prophylactic therapies for rare bleeding disorders.

Company-level read

Ticker impact

$COAGBullishHigh confidence
Context

JPMorgan initiated coverage on Hemab Therapeutics with an overweight rating and a $70 price target, a new analyst upgrade for the stock.

Expected impact

likely upward pressure as investors price in the new target

Evidence & confidence

The overweight rating and $70 target represent a 135% upside from current price, prompting buying interest.

Market effects

Positive sentiment may spill over to other biotech firms with similar pipelines.

Limited to US-listed biotech sector.

Minimal global impact beyond niche biotech investors.

Counterpoint

The stock remains volatile and early-stage; the high target may be overly optimistic.

Key entities

  • JPMorgan

    Initiated coverage with overweight rating and $70 target.

  • Hemab Therapeutics Holdings

    Biotech firm with pipeline assets sutacimig, HMB-002, HMB-003.

Related articles

$COAGMed

Hemab Therapeutics Holdings Inc (COAG) (Q3 2026) Earnings Call Highlights: Pivotal SOLARA

Hemab Therapeutics (COAG) discussed its SOLARA Phase III trial and HMB002 data in its Q3 2026 earnings call. CEO Benny Sorensen highlighted a 50%+ reduction in annualized treated bleed rate for von Willebrand disease, with data covering Type 1 and 2A patients. The trial requires a minimum annualized treated bleed rate of four at entry. HMB002 aims to correct underlying pathophysiology and is monitorable by clinicians.

$COAGMedAI 8/10

Hemab (COAG) Q3 2026 Earnings Call Transcript

Hemab (COAG) reported Q3 2026 progress, including Phase I trial initiation for HMB-003, Phase III trial start for sutacimig in Glanzmann thrombasthenia, and preclinical data for HMB-002. The company added Keli Walbert to its board and is building its commercial strategy. Sutacimig showed promising results in reducing bleeds, and HMB-003 aims to address heavy menstrual bleeding, a condition affecting millions of women.

$COAGMedAI 8/10

What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call

Hemab Therapeutics (COAG) reported a Q3 net loss of $27.3 million, up from $17.1 million a year earlier. The company plans to present updated Phase 2b data for its Factor VII deficiency treatment and new data for its von Willebrand disease treatment in 2027. Preclinical data for its heavy menstrual bleeding candidate will also be presented in December. R&D expenses rose to $24.6 million, driven by clinical program advances.

High

Why is Hemab Therapeutics stock sliding today?

Hemab Therapeutics (HMAB) shares fell 5.3% premarket after reporting a wider Q3 2026 net loss of $27.3M ($0.58/share), up from $17.1M YoY, due to higher R&D and admin costs. CEO Benny Sørensen noted pipeline progress, including a Phase 3 study start. Cash reserves were $430.2M. LifeSci Capital initiated coverage with an Outperform rating and $65 target. Broader market declines also pressured the stock.

Med

Hemab Therapeutics Posts Q3 2026 Net Loss of $27.3 Million

Hemab Therapeutics reported a Q3 2026 net loss of $27.3M, up from $17.1M a year earlier, due to increased R&D and administrative expenses. The company had $430.2M in cash and expects it to last until 2029. Key developments include a Phase 3 trial launch for sutacimig and a Phase 1 trial for HMB-003.

$COAGMedAI 8/10

Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Hemab Therapeutics Holdings, Inc. (COAG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone A